Cargando…
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
BACKGROUND: Pegylated arginine deiminase (ADI-PEG20; pegargiminase) depletes arginine and improves survival outcomes for patients with argininosuccinate synthetase 1 (ASS1)-deficient malignant pleural mesothelioma (MPM). Optimisation of ADI-PEG20-based therapy will require a deeper understanding of...
Autores principales: | Phillips, Melissa M., Pavlyk, Iuliia, Allen, Michael, Ghazaly, Essam, Cutts, Rosalind, Carpentier, Josephine, Berry, Joe Scott, Nattress, Callum, Feng, Shenghui, Hallden, Gunnel, Chelala, Claude, Bomalaski, John, Steele, Jeremy, Sheaff, Michael, Balkwill, Frances, Szlosarek, Peter W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227144/ https://www.ncbi.nlm.nih.gov/pubmed/37010783 http://dx.doi.org/10.1007/s43440-023-00480-6 |
Ejemplares similares
-
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023) -
A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma
por: Chan, Pui Ying, et al.
Publicado: (2022) -
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
por: Szlosarek, Peter W., et al.
Publicado: (2020) -
Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer
por: Szlosarek, Peter W., et al.
Publicado: (2021) -
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM
por: Przystal, Justyna Magdalena, et al.
Publicado: (2018)